#### NYSTATIN- nystatin suspension ATLANTIC BIOLOGICALS CORP.

-----


Nystatin Oral Suspension USP


[100,000 units per mL]

**Rx Only** 

#### DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Structural formula:





Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol ( $\leq 1\%$  v/v), artificial peppermint flavor, cherry flavor, citric acid, D&C Yellow No. 10, FD&C Red No. 40, glycerin, magnesium aluminum silicate, methylparaben, potassium phosphate dibasic, propylene glycol, propylparaben, purified water and sucrose.

#### CLINICAL PHARMACOLOGY

#### **Pharmacokinetics**

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

#### Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

#### INDICATIONS AND USAGE

Nystatin oral suspension is indicated for the treatment of candidiasis in the oral cavity.

#### CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

## PRECAUTIONS

#### General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

#### Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

#### Pregnancy

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

## **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

## Pediatric Use

See DOSAGE AND ADMINISTRATION.

## **ADVERSE REACTIONS**

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

*Gastrointestinal:* Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

*Dermatologic:* Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:* Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

## OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).

## DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

## HOW SUPPLIED

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available in a cherry, peppermint flavored, light creamy yellow, ready-to-use suspension, supplied in the following oral dosage forms: NDC 17856-0811-01 NYSTATIN 100,000 UNITS/ML 0.5ML ENFIT SYRINGE 120 ct UD NDC 17856-0811-02 NYSTATIN 100,000 UNITS/ML 1ML ENFIT SYRINGE 120 ct UD NDC 17856-0811-03 NYSTATIN 100,000 UNITS/ML 2ML ENFIT SYRINGE 120 ct UD NDC 17856-0811-04 NYSTATIN 100,000 UNITS/ML 5ML ENFIT SYRINGE 48 ct UD NDC 17856-0811-05 NYSTATIN 100,000 UNITS/ML 5ML CUP 72 ct UD

### Storage

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Avoid freezing.

### **DISTRIBUTED BY:**

### ATLANTIC BIOLOGICALS CORP

20101 N.E 16TH PLACE MIAMI, FL 33179

#### PRINCIPAL DISPLAY PANEL

NDC 17856-0811 NYSTATIN ORAL SUSPENSION, USP [100,000 units per mL] Alcohol ≤ 1% v/v SHAKE WELL Rx ONLY FOR INSTITUTIONAL USE ONLY SEE INSERT

## 17856-0811-01

Rev.01/19

See package insert for indications and dosage schedule

Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]. Protect from light. AVOID FREEZING \*\*\*\* Keep this and all Medication out of the reach of children

.....

17856-0811-01 NYSTATIN Dosage: 0.5 ML

Qty: 120 ENFIT Syringes



GTIN: 1785608111 S/N: 0000000000000 Exp: 10/08/19 Lot: 000000



Packaged by: Unit Dose Solutions Morrisville, NC 27560

RX

Distributed by: AtlanticBiologicals Corp, Miami FI 33179

Call to Reorder: 800.509.7592

17856-0	811-02	8.88	V Vase
		USPENSIC ENFIT SYF	
See packa	ige insert for indica	ations and dosage s	chedule
Room Temper	ature]. Protect fr	"°F).[See USP Co om light. AVOID F tion out of the rea	REEZING
17856-081 NYSTATIN		Dosage: 1	ML
	C C	Qty: 120 ENFIT §	Syringes
	GTIN: 1785608 S/N: 00000000 Exp: 10/08/19	112	Byringes RX
17856	GTIN: 1785608 S/N: 00000000	112	RX nit Dose Soluti 27560

## 17856-0811-03NYSTATIN ORAL SUSPENSION200,000 UNITS/2 ML ENFIT SYR

Rev.01/19

See package insert for indications and dosage schedule

Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]. Protect from light. AVOID FREEZING \*\*\*\* Keep this and all Medication out of the reach of children

17856-0811-03 NYSTATIN Dosage: 2 ML

Qty: 120 ENFIT Syringes



17856081103

GTIN: 1785608113 S/N: 0000000000003 Exp: 10/08/19 Lot: 000000

> Packaged by: Unit Dose Solutions Morrisville, NC 27560

Distributed by: AtlanticBiologicals Corp, Miami FI 33179

RX

Call to Reorder: 800.509.7592

#### śð 17856-0811-04 LIDOSE NYSTATIN ORAL SUSPENSION 500,000 UNITS/5 ML ENFIT SYR

See package insert for indications and dosage schedule

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from light. AVOID FREEZING \*\*\*\* Keep this and all Medication out of the reach of children

17856-0811-04 NYSTATIN

Dosage: 5 ML

Rev.01/19

Qty: 48 ENFIT Syringes



S/N: 0000000000004 Exp: 10/08/19 Lot: 000000

> Packaged by: Unit Dose Solutions Morrisville, NC 27560

RX

17856081104

Distributed by: AtlanticBiologicals Corp, Miami FI 33179

Call to Reorder: 800.509.7592

# 17856-0811-05

See package insert for indications and dosage schedule

Store at 20° to 25°C (68° to 77°F).[See USP Controlled Room Temperature]. Protect from light. AVOID FREEZING \*\*\*\* Keep this and all Medication out of the reach of children



Call to Reorder: 800.509.7592

NYSTATIN					
nystatin suspension					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:17	7856-0811(NDC:012	1-0810)
Route of Administration	ORAL				
Active Ingredient/Active Mo	iety				
Active Ingredient/Active Mo Ingredie	iety ent Name	Basis of Stren	ıgth	Strength	
	ent Name	<b>Basis of Stren</b> NYSTATIN	-	<b>Strength</b> 100000 [USP'U] in 1	L mL
Ingredi	ent Name		-	U U	mL
Ingredic NYSTATIN (UNII: BDF101C72E) (NYS	ent Name		-	U U	L mL
Ingredi	ent Name		-	U U	

Rev.01/19

CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
FD&C RED NO. 40 (UNII: WZB9127XOA)	
GLYCERIN (UNII: PDC6A3C0OX)	
METHYLPARABEN (UNII: A2I8 C7HI9 T)	
POTASSIUM PHOSPHATE, DIBASIC (UNII: CI71S98N1Z)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
SUCROSE (UNII: C151H8 M554)	
MAGNESIUM ALUMINUM SILICATE (UNII: 6 M3P6 4 V0 NC)	

## **Product Characteristics**

Co	lor	yellow (Light - Creamy)	Score	
Sha	ape		Size	
Fla	ivor	CHERRY (w/Peppermint)	Imprint Code	
Co	ntains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:17856-0811- 1	120 in 1 BOX, UNIT-DOSE	01/26/2021	
1		0.5 mL in 1 SYRINGE; Type 0: Not a Combination Product		
2	NDC:17856-0811- 2	120 in 1 BOX, UNIT-DOSE	01/26/2021	
2		1 mL in 1 SYRINGE; Type 0: Not a Combination Product		
3	NDC:17856-0811- 3	120 in 1 BOX, UNIT-DOSE	01/26/2021	
3		2 mL in 1 SYRINGE; Type 0: Not a Combination Product		
4	NDC:17856-0811- 4	48 in 1 BOX, UNIT-DOSE	01/26/2021	
4		5 mL in 1 SYRINGE; Type 0: Not a Combination Product		
5	NDC:17856-0811- 5	72 in 1 BOX, UNIT-DOSE	01/26/2021	
5		5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product		
6	NDC:17856-0811- 6	120 in 1 BOX, UNIT-DOSE	01/26/2021	
6		1 mL in 1 SYRINGE; Type 0: Not a Combination Product		
7	NDC:17856-0811- 7	120 in 1 BOX, UNIT-DOSE	01/26/2021	
7		2 mL in 1 SYRINGE; Type 0: Not a Combination Product		

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA203621	05/07/2019		

Establishment				
Address	ID/FEI	<b>Business Operations</b>		
	047437707	relabel(17856-0811), repack(17856-0811)		
	Address			

Revised: 1/2021

ATLANTIC BIOLOGICALS CORP.